Related Experiment Video
Updated: Jun 5, 2026
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Therapeutic vaccination for cancer immunotherapy: antigen selection and clinical responses
Astrid Geldmacher1, Anja Freier, Florian O Losch
1Clinical Research Group Tumor Immunology, Department of Dermatology, Skin Cancer Center Charité, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Background:
Because of its high specificity and low toxicity therapeutic vaccination is considered a desirable treatment for cancer. So far, however, the results of cancer vaccination trials have been disappointing, which is often attributed to the problem identifying appropriate vaccine antigens. Tumorassociated antigens are mostly autoantigens and therefore expected to be subject to immunosuppressive mechanisms. Cancer-testis antigens are the most prominent exception as, still being self, they are physiologically only expressed in immunopriviledged tissues and should therefore not induce autotolerance. This leads to the widely accepted hypothesis that cancer-testis antigens should be more efficient inducers of anti-tumor cellular immune responses than differentiation antigens. Aim of the study was to test this hypothesis by evaluating the published reports on clinical therapeutic vaccination trials for the objective clinical response rates to vaccination with cancer testis antigen vs. differentiation antigens.
Approach:
The results of vaccination clinical trials with cancer testis and/or differentiation antigens published in literature and databanks were analyzed for clinical outcome versus vaccine antigens. 21 publications on cancer testis antigen-based trials in which clinical outcome was reported according to WHO or RECIST were identified and analyzed.
Results:
The rate of objective responses to cancer testis antigen vaccines in 239 patients was 3.8% and for the 235 patients vaccinated with cancer testis plus 3 differentiation antigens 4.3% compared to 2.6% for the 496 patients vaccinated with differentiation antigens alone.
Conclusions:
Cancer testis antigen-based vaccines seem slightly superior over vaccines based on differentiation antigens providing support for the hypothesis.
Insights
Cancer-testis antigen vaccines show slightly better results than differentiation antigen vaccines in clinical trials. This supports the hypothesis that cancer-testis antigens may be more effective for cancer immunotherapy.
Area of Science:
- Oncology
- Immunology
- Vaccine Development
Background:
- Therapeutic cancer vaccination is a promising strategy due to its specificity and low toxicity.
- Clinical trial outcomes for cancer vaccination have been disappointing, often due to challenges in identifying effective antigens.
- Cancer-testis antigens, unlike tumor-associated antigens, are not subject to self-tolerance, making them promising candidates for cancer immunotherapy.
Purpose of the Study:
- To evaluate the hypothesis that cancer-testis antigens are more effective than differentiation antigens in inducing anti-tumor immune responses.
- To compare objective clinical response rates in patients receiving cancer-testis antigen-based vaccines versus differentiation antigen-based vaccines.
Main Methods:
- A systematic analysis of published clinical therapeutic vaccination trials was performed.
- Data from 21 publications reporting clinical outcomes (WHO or RECIST criteria) for cancer-testis antigen-based trials were analyzed.
- Response rates were compared between vaccines utilizing cancer-testis antigens, differentiation antigens, or a combination.
Main Results:
- The objective response rate for cancer-testis antigen vaccines was 3.8% (239 patients).
- Vaccines combining cancer-testis and differentiation antigens showed a 4.3% response rate (235 patients).
- Differentiation antigen-based vaccines alone yielded a 2.6% objective response rate (496 patients).
Conclusions:
- Cancer-testis antigen-based vaccines demonstrated a slightly higher response rate compared to differentiation antigen-based vaccines.
- These findings provide support for the hypothesis that cancer-testis antigens may be superior for therapeutic cancer vaccination.
- Further research into cancer-testis antigens could lead to more effective cancer immunotherapies.
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...